

10/12/01  
JCS 2525 U.S. PTO

8.22.01

A | box seq

<b>UTILITY PATENT APPLICATION TRANSMITTAL</b> <small>(Only for new nonprovisional applications under 37 CFR 1.53(b))</small>		Attorney Docket No. P0738/7001/ERP/KA
First Named Inventor or Application Identifier		
Richard T. Lee, et al.		
Express Mail Label No. EL844533521US		10/12/01 10972 097944249
Date of Deposit August 21, 2001		

<b>APPLICATION ELEMENTS</b> <small>See MPEP chapter 600 concerning utility patent application contents</small>		<b>ADDRESS TO:</b> Box Patent Application Commissioner for Patents Washington, DC 20231
<p>1. <input type="checkbox"/> Fee Transmittal Form <i>(Submit an original, and a duplicate for fee processing)</i></p> <p>2. <input checked="" type="checkbox"/> <b>Applicant claims small entity status.</b> See 37 CFR 1.27.</p> <ul style="list-style-type: none"> <li><input type="checkbox"/> Statement filed in prior application, Status still proper and desired.</li> </ul> <p>3. <input type="checkbox"/> Specification [Total pages 86] 74 - pages description 1 - page abstract 11 - pages claims 78 - Total claims</p> <p>4. <input checked="" type="checkbox"/> Drawing(s) (35 USC 113) [Total sheets 1] <input type="checkbox"/> Informal <input checked="" type="checkbox"/> Formal [Total drawings 1]</p> <p>5. <input type="checkbox"/> Oath or Declaration [Total pages ]  <ul style="list-style-type: none"> <li><input type="checkbox"/> Newly executed (original or copy)</li> <li><input type="checkbox"/> Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional with Box 18 completed) <i>[Note Box 6 below]</i></li> <li><input type="checkbox"/> <b>DELETION OF INVENTOR(S)</b> Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).</li> </ul> </p> <p>6. <input type="checkbox"/> Incorporation by Reference <i>(usable if Box 5b is checked)</i> The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein. See 19.</p> <p>7. <input checked="" type="checkbox"/> <b>Application Data Sheet, See 37 CFR 1.76</b></p>		
<b>ACCOMPANYING APPLICATION PARTS</b>		
<p>10. <input type="checkbox"/> Assignment Papers/cover sheet &amp; documents(s)</p> <p>11. <input type="checkbox"/> 37 CFR 3.73(b) Statement <i>(when there is an assignee)</i> <input type="checkbox"/> Power of Attorney</p> <p>12. <input type="checkbox"/> English Translation of Document <i>(if applicable)</i></p> <p>13. <input type="checkbox"/> Information Disclosure Statement PTO-1449 <input type="checkbox"/> Copies of IDS Citations</p> <p>14. <input checked="" type="checkbox"/> Preliminary Amendment</p> <p>15. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) <i>(Should be specifically itemized)</i></p> <p>16. <input type="checkbox"/> Certified Copy of Priority Document(s) <i>(if foreign priority is claimed)</i></p> <p>17. <input type="checkbox"/> Request and Certification Under 35 U.S.C. §122(b)(2)(B)(ii)</p> <p>18. <input checked="" type="checkbox"/> <b>Other:</b> This application claims priority under 35 U.S.C. §119(e) from Provisional U.S. Patent Application Serial No. 60/227,159 filed on August 22, 2000, entitled DIAGNOSIS AND TREATMENT OF CARDIOVASCULAR CONDITIONS. The contents of the provisional application are hereby expressly incorporated by reference.</p>		

19. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information below or in the body of the application, or a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:

Continuation  Divisional  Continuation-in-part (CIP) of prior application No.

Cancel in this application claims before calculating the filing fee.

Amend the specification by inserting before the first line of the specification on page 1, after the title, the following:

-- This application is a  Continuation  Continuation -in-part (CIP) of prior application No:

**Prior application information:** *Examiner*

**Group Art Unit:**

For CONTINUATION OR DIVISIONAL APPS ONLY: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

**20. CORRESPONDENCE ADDRESS**

*Correspondence address below*

**CUSTOMER NUMBER:**



**23628**

**OR**

ATTORNEY'S NAME	Elizabeth R. Plumer, Reg. No. 36,637				
FIRM NAME	Wolf, Greenfield & Sacks, P.C.				
ADDRESS	600 Atlantic Avenue				
CITY	Boston	STATE	MA	ZIP	02210
COUNTRY	USA	TELEPHONE	(617) 720-3500	FAX	(617) 720-2441

**21. SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED**

NAME	Konstantinos Andrikopoulos, Reg. No. P-48,915
SIGNATURE	Konstantinos Andrikopoulos
DATE	August 21, 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Richard T. Lee, et al.  
Serial No. Not Yet Assigned  
Filed: August 21, 2000  
For: DIAGNOSIS AND TREATMENT OF CARDIOVASCULAR  
CONDITIONS  
Examiner: Not Yet Assigned  
Art Unit: Not Yet Assigned



BOX PATENT APPLICATION  
COMMISSIONER FOR PATENTS  
WASHINGTON, D.C. 20231

Sir:

STATEMENT PURSUANT TO 37 C.F.R. §1.821(f)

This statement is made pursuant to 37 C.F.R. §1.821(f). Applicants enclose herewith an original written copy of the Sequence Listing and a computer readable diskette. Applicants' representative states that the information recorded in the computer readable form is identical to the written Sequence Listing and that the Sequence Listing contains no new matter.

Respectfully submitted,

*Konstantinos Andrikopoulos*  
Konstantinos Andrikopoulos, Reg. No. P-48,915  
WOLF, GREENFIELD & SACKS, P.C.  
600 Atlantic Avenue  
Boston, MA 02210-2211  
(617)720-3500

Attorney's Doc. No.: P0738/7001 (ERP/KA)  
August 21, 2001  
x08/22/01